Nodality Appoints Dr. Greg Critchfield to Board of Directors
South San Francisco, CA, December 13, 2010Nodality, Inc., an emerging biotechnology company, today announced that Gregory Critchfield, M.D., M.S., has joined the company's Board of Directors.
Dr. Critchfield, brings over 20 years of senior management experience in the diagnostics business, most recently serving as President of Myriad Genetic Laboratories, Inc. until his retirement earlier this year. During his tenure he launched seven novel diagnostics products across multiple technology platforms including several novel diagnostic test services for patients with cancer. Prior to Myriad, he was responsible for innovation and medicine in the spin-out of Quest Diagnostics, Inc. from Corning Clinical Laboratories, serving as Quest's Chief Medical and Science Officer.
“Greg's experience creating and commercializing novel diagnostic products and technologies is unsurpassed,” said Dr. David Parkinson, Chief Executive Officer of Nodality. “We are pleased to have him join our Board. His ideas, knowledge and experience will no doubt assist Nodality in utilizing Single Cell Network Profiling (SCNP) in clinical test applications to better link individual patients with appropriate therapies.”
“Nodality has pioneered an incredibly powerful technology which measures specific signaling changes at the single cell level,” said Dr. Critchfield. “Nodality's SCNP technology has now created the possibility to classify individual patients into clinically and therapeutically meaningful disease sub-groups. Nodality's work provides novel understanding of biologic cell signals at the core of both cancer and autoimmune diseases. This exciting technology has tremendous potential in both clinical medicine and drug development.”
Dr. Critchfield received a Bachelor's Degree in Microbiology with a minor in Chemistry from Brigham Young University in 1976, a Medical Degree from the University of Utah in 1980, and a Master's Degree in Biophysical Sciences at the University of Minnesota in 1985. There he also completed fellowships in Clinical Chemistry and in Health Information Sciences sponsored by the National Library of Medicine and boarded in Clinical Pathology.
About NodalityNodality is a private, South San Francisco-based biotechnology company focused on improving the development and clinical use of therapeutics in cancer and autoimmune disease through the application of its proprietary Single Cell Network Profiling technology platform. Through its ability to functionally characterize cell signaling networks at the single cell level of resolution Nodality is committed to the biological characterization of individual patients to optimally match them with biologically-targeted treatments.
About Single Cell Network ProfilingSingle Cell Network Profiling (SCNP) is a proprietary technology licensed from Stanford University to characterize cell signalling networks in patients with cancer and autoimmune diseases. SCNP, by measuring functional signaling network behavior in single cells, has several advantages over other currently used molecular technologies. These include unprecedented insight into the presence and clinical meaning of cellular heterogeneity including the importance of rare cells such as drug-resistant and stem cells. As the technology has widespread application in both preclinical and clinical drug development, Nodality is also utilizing SCNP in collaboration with drug developers to decrease the time, cost, and risks of drug development.